Bob Gatty, a former congressional aide, covers news from Washington for Urology Times.
A new study by the Partnership for Health Analytic Research appears to bolster arguments by independent physicians and those who operate outpatient clinics that they are at a substantial financial disadvantage against hospitals when it comes retaining profits from the administration of injectable and infused drugs.
A new study by the Partnership for Health Analytic Research (PHAR) appears to bolster arguments by independent physicians and those who operate outpatient clinics that they are at a substantial financial disadvantage against hospitals when it comes retaining profits from the administration of injectable and infused drugs.
The analysis, completed by Jesse D. Ortendahl, MS, and Katalin Bognar, PhD, finds that hospitals retained 91% of profits from physician-administered medicines while serving 53% of patients receiving physician-administered medicines. Independent practices retained just 9% while serving 47% of patients.
Also by Bob Gatty: Advocates work toward Office of Men’s Health
PHAR, which counts a substantial number of drug manufacturers as clients, said its research also suggests that hospitals are earning more from administering medicines than the manufacturers who created them. For every $100 spent on physician-administered medicines in the hospital outpatient setting, the hospital retains $58, while the manufacturer receives less than $42, the report said.
Efforts to obtain comments from the American Hospital Association (AHA) and the Federation of American Hospitals were unsuccessful. However, in its 2019 Advocacy Agenda, AHA stresses the importance of “establishing fair and sustainable drug pricing and reimbursement.” AHA also calls on Congress to “restore vital funding and prevent further cuts to the 340B drug savings program, which allows hospitals to provide programs that improve access to care in their communities.”
Dr. Holton: Study emphasizes unfair disadvantage
Mara R. Holton, MD, CEO/president of Anne Arundel Urology in Annapolis, MD, and vice chair of health policy at LUGPA, said the PHAR study emphasizes what LUGPA contends is an unfair and anticompetitive marketplace disadvantage for physician-operated clinics.
Next: “How can we compete with these large health systems that have such extraordinary advantages?”“Fundamentally, our concerns are the preservation of the independent practice setting as a cornerstone of the American health care system, representing a unique and integral venue for the delivery of high-quality and cost-efficient health care services,” Dr. Holton told Urology Times.
“How can we compete with these large health systems that have such extraordinary advantages?” she asked, pointing to the huge disparity in profits from physician-administered medicines. “These are identically credentialed providers, and there is no difference in the patient’s experience, except for convenience.”
That’s why, she says, LUGPA and other organizations have tried to convince Congress and the Centers for Medicare & Medicaid Services (CMS) to “level the playing field.” That would include reforming the 340B Drug Pricing Program, which Dr. Holton contends “creates a slush fund of cash that hospitals have been able to use to acquire physicians’ practices and increase vertical consolidation, thus driving up cost.”
In addition, said Dr. Holton, “There are several statutory and regulatory provisions that promote continued hospital consolidation, escalate the rise in health care costs, and imperil the survival of independent practices.”
These, she said, include:
• disproportionate reimbursement for the same services performed by hospital outpatient departments (site non-neutrality)
• benefits both in lower acquisition cost for pharmacy (340B for example) and much higher reimbursement for the same drug administration, as shown in the PHAR study
• reform of fraud and abuse laws (federal Stark physician self-referral law and the federal Anti-Kickback Statute).
LUGPA joined with the AUA, American Association of Clinical Urologists, and several other organizations to sign a letter in April in support of H.R. 2282 and its companion in the Senate, S.966, “The Medicare Care Coordination Improvement Act of 2019,” which would clear the way for physicians to participate and succeed in APMs without running afoul of the Stark law.
The letter contends that the Stark law prohibits payment arrangements that consider the volume or value of referrals or other business generated by the parties.
“Congress recognized the Stark Law was a barrier to care coordination long ago when it authorized the Secretary at the Department of Health and Human Services (HHS) to waive the self-referral and anti-kickback prohibitions for Accountable Care Organizations,” the letter adds. “MACRA’s full potential can only be achieved by modernizing this law for physician-led APMs as well.”
H.R. 2282 would remove some of these barriers by:
• providing HHS the same authority to waive Stark provisions and associated fraud and abuse laws for physicians seeking to develop and operate APMs as was provided to accountable care organizations in the Affordable Care Act
• removing the “volume or value” prohibition in the Stark law so physician practices can incentivize physicians to abide by best practices and succeed in value-based alternative payment models.
Trump admin interested in improving process
Meanwhile, Dr. Holton said the Trump administration has shown “a lot of interest” in improving the regulatory process regarding Stark so practices can participate in those models.
“CMS has been very forward thinking about recognizing that outpatient physician care can be provided at significantly less cost and has done a number of things to help,” Dr. Holton said. But much more needs to be done, she said, including congressional reform of Stark.
“In some cases, practices are able to own surgery centers, in some, they are not. But that speaks to the fact that on the regulatory side, CMS has been helpful in recognizing that independent practices offer a meaningful way to reduce health care costs overall. It is a nod, not a bow.”
She said LUGPA fully supports CMS’ Sept. 26 announcement of its Omnibus Burden Reduction (Conditions of Participation) final rule, which the agency says “strengthens patient safety by removing unnecessary, obsolete, or excessively burdensome health regulations on hospitals and other health care providers.”
CMS says it will save providers an estimated 41.4 million hours previously spent on paperwork annually, with a projected savings of $8 billion over 10 years.
Comments? Let us know by sending us an email at email@example.com